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A b s t r A c t
Multidrug-resistant (MDr) Acinetobacter baumannii (Acb) is a rapidly emerging pathogen in 
healthcare settings. the aim of this study was to evaluate the predictors of poor outcome 
in patients with MDr Acb. this is the first report documenting factors influencing survival in 
patients with MDr Acb in this tertiary hospital. this study is a prospective of the hospital 
epidemiology database. A total of 73 patients with 84 Acb isolates were obtained between 
August 2009 and october 2010 in this hospital. in the present study, the 30-day mortality 
rate was 39.7%. of 84 Acb isolates, 50 (59%) were MDr, nine (11%) were pan-resistant, and 
25 (30%) were non-MDr. the non-MDr isolates were used as the control group. the factors 
significantly associated with multidrug resistance included previous surgeries, presence 
of comorbidity (renal disease), use of more than two devices, parenteral nutrition, and 
inappropriate antimicrobial therapy. significant predictors of 30-day mortality in the 
univariate analysis included pneumonia, diabetes mellitus, renal disease, use of more than 
two devices, and inappropriate antimicrobial therapy administered within two days of the 
onset of infection. the factors associated with mortality in patients with MDr Acb infection 
in this study were: age ≥ 60 years, pneumonia, diabetes mellitus, renal disease, use of more 
than two invasive procedures, and inappropriate antimicrobial therapy. Vigilance is needed 
to prevent outbreaks of this opportunistic and deadly pathogen.
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Introduction
Acinetobacter baumannii (Acb), found ubiquitously in the 
environment, is an aerobic Gram-negative rod which is 
a non-fermenter of glucose.1 Multidrug-resistant (MDr) 
Acb is a rapidly emerging pathogen in healthcare settings. 
carbapenems are often used as last resort antibiotics to treat 
MDr gram-negative bacteria infections.2 the aim of this 
study was to evaluate predictors of poor outcome in patients 
infected with MDr Acb.
Methods
Setting
this research was approved by the Microbiology Laboratory 
and by the Ethics committee on Human research of the 
Universidade federal de Uberlândia (opinion no. 479/09). the 
university hospital is a 530-bed teaching tertiary safety net 
hospital. the intensive care unit has 30 beds and combines 
general medical unit and a semi-closed surgical unit.
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Study design
this study was a prospective study of the hospital epidemiology 
database and included 84 isolates of Acb from 73 patients for 
the period of August 2009 to october 2010. Patients with more 
than one isolate were counted only once. Documented patient 
demographics and potential risk factors included diagnosis, 
duration of hospitalization, intensive care unit (icU) stay, 
patient location, age, gender, race, previous hospitalization, 
previous surgeries, previous antibiotic use, any kind of medical 
intervention, such as the need for mechanical ventilation, central 
vascular catheters, tracheostomy, and parenteral nutrition, and 
the patients’ medical histories, including underlying malignancy, 
diabetes mellitus, renal disease, acquired immunodeficiency 
syndrome (AiDs), and chronic obstructive lung disease. the 
source of the Acb isolates was also noted. 
Identification and characterization of MRD Acb
identification of Acinetobacter and susceptibility testing was 
performed using Vitek 2. testing was carried on according to 
the manufacturer’s specifications for this instrument, and was 
done in accordance with the clinical and Laboratory standards 
institute3 recommended practices.
An isolate was deemed pan-resistant if it was resistant to all 
commonly tested antibiotics except colistin. MDr Acb isolates 
were defined as those resistant to more than three classes of 
antibiotics. 
Appropriate therapy was defined as one or more agents 
active against the Acb complex, given with adequate dosage 
and route of administration, not later than 24h after the culture 
was obtained.
Statistical analysis
Patients were stratified into two groups according to multidrug 
resistance. continuous variables were expressed as mean ± 
standard deviation, and categorical variables were expressed 
as a percentage of the total number of patients analyzed. 
the chi-square test with Yates’s correction or fisher’s exact 
test were used for categorical variables. A p-value less than 
0.05 was considered statistically significant. All statistical 
analyses were performed with the statistical Package for 
social sciences, version 17 (sPss inc. – chicago, iL, UsA).
Results
A total of 73 patients were studied and 84 Acb isolates were 
obtained between August 2009 and october 2010 in the tertiary 
hospital. these infections were endemic. the mean age of the 
patients was 57.8 years, and 49 (67.1%) patients were male. 
twenty three (31.5%) patients underwent surgeries. the most 
frequent comorbidity was renal disease in 22/73 (30.1%), 
followed by malignancy in 10/73 (13.7%), and diabetes mellitus 
in 8/73 (10.9%). forty seven patients (64.4%) required more than 
two devices; mechanical ventilation in 45 patients (61.6%); 
central vascular catheters in 44 patients (60.3%); tracheostomy 
in 25 patients (34.2%); and parenteral nutrition in 25 patients 
(34.2%). Empiric antimicrobial therapy was administered in 
58 (79.1%) patients. the rate of inappropriate antimicrobial 
therapy was 41.1%. the 30-day mortality rate was 39.7%. 
Patient characteristics, underlying conditions, and disease-
related characteristics are listed in table 1.
the sites of Acb isolation in patients were blood stream and 
vascular catheters in 33 (39.3%), respiratory tract in 27 (32.1%), 
and urinary tract in 15 (17.8%).
of the 84 Acb isolates, 50 (59%) were MDr, nine (11%) were pan-
resistant, and 25 (30%) were non-MDr. Using the non-MDr isolates 
as the control group, the risk factors for the acquisition of MDr 
Acb were calculated (table 2). the factors significantly associated 
with multidrug resistance included previous surgery, presence 
of comorbidity (renal disease), use of more than two devices, 
parenteral nutrition, and inappropriate antimicrobial therapy.
significant predictors of 30-day mortality in the univariate 
analysis included patients with pneumonia, diabetes mellitus, 
renal disease, use of more than two devices, and inappropriate 
antimicrobial therapy administered within two days of 
infection onset (table 3).
Characteristics Patients 
n = 73 (%)
Age, years  
median years (minimum-maximum)
57.8 (0-94)
Gender (male) 49 (67.1)
Duration of hospital stay before Acb infection  
median days (minimum-maximum)
49.5 (1-224)
Admission
 clinic 49 (67.1)
 surgical 7 (9.6)
 trauma 17 (23.3)
Admitted to intensive care unit 25 (34.2)
Any surgical procedure 23 (31.5)
comorbidity
 Diabetes mellitus 8 (10.9)
 renal disease 22 (30.1)
 Malignancy 10 (13.7)
 Acquired immunodeficiency syndrome 2 (2.7)
 chronic obstrutive lung disease 2 (2.7)
invasive procedures
 More than two 47 (64.4)
 central venous catheter 44 (60.3)
 Mechanical ventilation 45 (61.6)
 tracheostomy 25 (34.2)
 Parenteral nutrition 25 (34.2)
 Empiric antimicrobial therapy 58 (79.4)
 inappropriate antimicrobial therapy 30 (41.1)
 total mortality (30 days after infection) 29 (39.7)
Acb, Acinetobacter baumannii.
Table 1 - Patient characteristics, underlying conditions 
and disease-related characteristics in patients with 
Acinetobacter baumannii (Acb) infections from August 
2009 to October 2010 at the Hospital das Clínicas, 
Universidade Federal de Uberlândia, MG, Brazil
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Characteristics Acb MDR 
n = 49(%)
Acb-non-MDR 
n = 24(%)
p* OR 
(95% CI)
Age, years 
median years (minimum-maximum)
62 (18-93) 46 (2m-84) nA
Gender (male) 31 (63.3) 17 (70.8) 014 0.71 (0.22-2,28)
Duration of hospital stay before Acb infection 
median days (minimum-maximum)
55 (1-224) 36 (1-112) nA
Presence in intensive care unit 15 (30.6) 10 (41.7) 0.45 0.62 (0.2-1,92)
comorbidity
 Diabetes mellitus 5 (10.2) 3 (12.5) 1.00 0.8 (0.14-4,71)
 Acute renal failure 15 (30.6) 7 (29.2) 0.02 1.07 (0.33-3,57)
 Malignancy 8 (16.3) 2 (8.3) 0.48 2.15 (0.37-16.1)
 Acquired immunodeficiency syndrome 2 (4.1) 0 1.00 indefinite
 chronic obstrutive lung disease 1 (2.1) 1 (4.2) 1.00 0.48 (0.01-18.51)
invasive procedures
 More than two 38 (77.6) 9 (37.5) 0.001 5.76 (1.76-19.4)
 central venous catheter 31 (63.3) 13 (54.2) 0.62 1,46 (0.48-4.41)
 Mechanical ventilation 32 (65.3) 13 (54.2) 0.50 1.59 (0.53-4.85)
 tracheostomy 19 (38.8) 6 (25) 0.36 1.9 (0.57-6.52)
 Parenteral nutrition 17 (34.7) 8 (33.3) 0.02 1.06 (0.34-3.39)
 Empiric antimicrobial therapy 40 (81.3) 18 (75) 0.54 1.48 (0.39-5.52)
 inappropriate antimicrobial therapy 20 (40.8) 10 (41.7) 0.03 0.97 (0.32-2.92)
 total mortality (30 days after infection) 21 (42.9) 8 (33.3) 0.28 1.50 (0.48-4.72)
Acb, Acinetobacter baumannii; Acb MDr, multidrug resistant Acinetobacter baumannii; Acb-non-MDr, non-multidrug resistant Acinetobacter 
baumannii; or, odds ratio; 95% ci, confidence interval; nA, non applicable; *p ≤ 0,05.
Table 2 - Risk factors for 73 multi-resistant Acb isolates 
Discussion
infections caused by Acb are of great concern worldwide. this 
is the first report documenting factors influencing survival in 
patients with MDr Acb infection in this hospital. Although 
many studies across the world on Acb have been reported, 
most have involved populations with both monomicrobial and 
polymicrobial infections. in the present study, only patients 
with monomicrobial infection were selected. Acb is usually 
considered a healthcare-associated pathogen, and reports 
on the incidence of nosocomial Acb outbreaks has been 
increasing.4 several investigators have found an association 
of MDr Acb with co-morbidities.5 the lethality rate due to 
Acb is high, ranging from 22% to 59%.6,7 in the present study, 
the 30-day mortality rate was 39.7%. the significant factors 
for MDr Acb infection were any surgical procedure, acute 
renal failure, more than two invasive procedures, parenteral 
nutrition, and inappropriate antimicrobial therapy. these 
findings are consistent with other reports, but this is the 
first prospective study in this hospital to provide detailed 
epidemiological characteristics and outcomes of patients with 
Acb infections. 
several studies have demonstrated that the severity of 
the underlying diseases, ventilator-associated pneumonia, 
or wound infection can be sources of bacteremia and that 
long-term ventilator support, recent surgery, carbapenem 
resistance, and inappropriate use of antibacterial agents are 
associated with poor outcome in Acinetobacter bacteremia.8,9 
Although the available evidence suggests a significant effect 
on patient outcome in terms of prolonged hospital stay 
and duration of mechanical ventilation, the attributable 
mortality of MDr infections remains arguable.10,11 in the 
present study, bacteremia, surgical procedure, malignancy, 
central venous catheter, mechanical ventilation, parenteral 
nutrition, and empiric antimicrobial therapy were not 
significantly associated with 30-day mortality. Univariate 
analysis showed that pneumonia, diabetes mellitus, renal 
disease, use of more than two devices, and inappropriate 
antimicrobial therapy administered within two days of 
infection onset were associated with increased mortality. 
the impact of inappropriate antimicrobial therapy 
and antibiotic resistant strains are not negligible and 
should, therefore, be verified by further prospective 
and randomized studies.
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Predictive factors Mortality/total (%) Univariate analysis 
p* (OR)
Age (years)
 ≥ 60 21/40 0.02* (3.45)
 < 60 8/33
bacteremia
 MDr 12/21 0,62 (1.87)
 non-MDr 5/12
Pneumonia
 MDr 11/23 0.002* (indefinite)
 non-MDr 0/14
surgical procedure
 Yes 5/23 0.06 (0.3)
 no 24/50
Diabetes mellitus
 Yes 6/8 0.05* (5.48)
 no 23/65
renal disease
 Yes 15/22 0.002* (5.66)
 no 14/51
Malignancy
 Yes 2/10 0.29 (0.33)
 no 27/63
Use more than two invasive procedures
 Yes 12/47 0.002* (0.18)
 no 17/26
central venous catheter
 Yes 21/44 0.13 (2.4)
 no 8/29
Mechanical ventilation
 Yes 19/45 0.75 (1.32)
 no 10/28
Parenteral nutrition
 Yes 9/25 0.82 (0.79)
 no 20/48
Empiric antimicrobial therapy
 Yes 22/58 0.74 (0.70)
 no 7/15
inappropriate antimicrobial therapy
 Yes 22/30 0.0000032* (14.14)
 no 7/43
MDr, multidrug-resistant; or, odds ratio; *p ≤ 0,05.
Table 3 - Univariate analysis of predictive factors of mortality in patients with Acinetobacter baumannii infection during 
the period of August 2009 to October 2010
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Conclusion
the factors associated with mortality in patients with MDr 
Acb infection in this study were age ≥ 60 years, pneumonia, 
diabetes mellitus, renal disease, use of more than two invasive 
procedures, and inappropriate antimicrobial therapy. Acb has 
emerged as an important nosocomial pathogen and infections 
due to MDr strains have been difficult to control, especially in 
intensive care units. Vigilance is needed to prevent outbreaks 
of this opportunistic and deadly pathogen.
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